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Abstract: Female sex is an independent risk factor for development of torsade de pointes (TdP)-type arrhythmias in both 
congenital and acquired long QT syndrome (LQTS). In females, QTc interval and TdP risk vary during the menstrual cy-
cle and around delivery. Biological experiments including single-cell current recordings with the patch-clamp technique 
and biochemical experiments show that progesterone modulates cardiac K
+ current and Ca
2+ current via the non-genomic 
pathway of the progesterone receptor, and thus the cardiac repolarization duration, in a concentration-dependent manner. 
Incorporation of these biological findings into a computer model of single-cell and coupled-cell cardiomyocytes simulates 
fluctuations in QTc interval during the menstrual cycle with reasonable accuracy. Based on this model, progesterone is 
predicted to have protective effects against sympathetic nervous system-induced arrhythmias in congenital LQTS and 
drug-induced TdP in acquired LQTS. A combined biological and computational approach may provide a powerful means 
to risk stratify TdP risk in women.  
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INTRODUCTION 
  A growing body of evidence suggests that clinical ar-
rhythmia syndromes emerge as a result of complicated inter-
actions of multiple endogenous and environmental factors. A 
combined approach using patch-clamp study and computer 
simulation study is a powerful means for investigating the 
influence of multiple interacting factors on the development 
of clinical symptoms. In this mini-review, we will discuss 
our recent work using a combined biological and computa-
tional approach to predict arrhythmic risks in women. 
1. ARRHYTHMIAS IN LONG QT SYNDROME 
(LQTS) IN WOMEN 
  LQTS is a cardiac arrhythmia syndrome characterized by 
prolonged QT intervals on the 12-lead surface electrocardio-
gram, polymorphic ventricular tachyarrhythmias with unique 
morphology, called torsade de pointes (TdP), and syncope 
and sudden death. Experiments using multicellular wedge 
prepatnion indicate that TdP is triggered by early afterdepo-
larization (EAD) followed by intramural phase 2 reentry, 
which is based on hetelogeneous prolongation myocardial 
action potential duration (APD) [3]. APD prolongation is 
caused by either suppression of outward currents including 
transient outward current (Ito), and rapidly-activating and 
slowly-activating delayed rectifier K
+ current (IKs and IKr), 
or/and enhancement of inward currents including L-type 
Ca
2+ current (ICa,L) and persistent Na
+ current (INa). 
  LQTS occurs as a congenital form or an acquired form. 
In both congenital and acquired LQTS, female sex is an in-
dependent risk factor for the development of TdP [1, 2]. In  
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females, there are dynamic fluctuations in QTc interval and 
the risk of TdP during the menstrual cycle [4]. Although 
several previous studies did not find QTc interval differences 
among the different menstrual phases [5, 6], a recent study 
analyzing various parameters of cardiac repolarization finds 
that repolarization duration is shorter in the luteal phase than 
in the follicular phase by about 10 msec [6]. Ibutilide is a 
class III antiarrhythmic agent that prolongs QTc interval in a 
dose-dependent manner, and is used for termination of atrial 
fibrillation and atrial flutter. QTc prolongation induced by 
ibutilide is the greatest during menses (63 msec), intermedi-
ate in ovulation (59 msec), and the least in the luteal phase 
(53 msec) [5]. In these studies [5, 7], serum sex hormone 
level was determined: serum progesterone level was higher 
in the luteal phase than in the follicular phase, during men-
ses, and in ovulation, while serum 17-estradiol level was 
not significantly different between the luteal phase and the 
follicular phase. Thus, progesterone is suggested to be re-
sponsible for differences in cardiac repolarization duration 
and in ibutilide-induced QTc prolongation during the men-
strual cycle. 
  In post-menopausal women, although earlier studies re-
port conflicting data for effects of hormone replacement 
therapy on QTc interval [8-10]. a recent study consisting of a 
large study population indicates that hormone replacement 
therapy with estrogen alone causes slight but significant pro-
longation of QTc interval by about 2 msec, while combina-
tional hormone replacement therapy with estrogen and pro-
gestin consistently shortens QTc interval by about 1 msec 
[11]. Effects of pregnancy in LQTS patients were also exam-
ined [12, 13]. In careful survey of arrhythmia events in con-
genital LQTS patients around delivery, new-onset of ar-
rhythmia events increased postpartum where progesterone 
level falls dramatically compared to before or during preg-
nancy [12]. Taken together, the luteal hormone, progester-A Combined Approach Using Patch-Clamp Study  Current Cardiology Reviews, 2008, Vol. 4, No. 4    245
one, is strongly suggested to have protective effects against 
long QT-associated arrhythmias. 
2. GENOMIC EFFECTS OF PROGESTERONE ON 
CARDIAC ION CHANNELS 
  Progesterone belongs to lipophilic gonadal steroid hor-
mone family, whose canonical pathway is to permeate into 
cell across surface membrane, binds to intracellular receptor, 
translocates into the nucleus as a ligand/receptor complex 
form, and binds to a gene containing a hormone responsive 
element (Fig. 1) [14-16]. In addition to this “genomic ac-
tion”, for the last decade sex hormones have been shown to 
exhibit rapid actions which cannot be explained by genomic 
action and are referred to as “non-genomic action” (Fig. 1)
[17-20]. Non-genomic action takes place in a membrane-
delimited manner: PI3-kinase/Akt-dependent activation of 
endothelial nitric oxide synthase (eNOS) [21, 22] and activa-
tion of MAP-kinase [23, 24] are the two most well character-
ized signaling pathways.  
  Previous studies of effects of progesterone on cardiac ion 
channels have mostly dealt with its genomic actions. Song et 
al. [25] examined effects of gonadal steroids on expression 
of transient outward current channels, KV4.3, using a myo-
metrium heterologous expression as a model system. They 
found that 4 days-injection of 17-estradiol (50 g/ml) de-
creased expression of KV4.3, whereas injection of progester-
one (3 mg/ml) did not affect KV4.3 expression. The 1C 
subunit of the L-type Ca
2+ current (ICa,L) channel can be de-
tected as a 240 kDa long form (1C long) and a 190 kDa 
short form (1C short). In myometrium, 17-estradiol de-
creased the long 1C form/short 1C form (L/S ratio), while 
progesterone increased the L/S ratio; in brain or heart, either 
17-estradiol or progesterone did not change the L/S ratio 
[26]. Thus, the genomic effects of progesterone on cardiac 
repolarization are currently undefined and cannot explain a 
protective effect of progesterone against TdP risk. 
3. NON-GENOMIC EFFECTS OF PROGESTERONE 
ON CARDIAC ION CURRENTS 
  Major currents determining cardiac repolarizaion are IKs,
IKr, and ICa,L in human and guinea-pig. Ito and ICa,L are critical 
in mouse and rat [27, 28]. Thus, we used cardiac myocytes 
isolated from guinea pig left ventricle to investigate acute 
effects of progesterone. Sympathetic nervous system (SNS) 
stimulation is a critical triggering factor for TdP in LQTS 
patients [29], and thus we examined both the basal condition 
and the SNS stimulation-mimicked condition with isoproter-
enol application or with intracellular dialysis of cAMP and 
okadaic acid (OA). Progesterone at a concentration of 100 
nM shortened APD both in the basal condition and the SNS-
stimulated condition.
29 Progesterone-induced APD shorten-
ing is via the non-genomic pathway, since progesterone-
induced APD shortening was observed within a few minutes, 
reached steady-state within 10 min, and was inhibited by a 
specific progesterone receptor inhibitor, mifepristone (1 
M).
  The ionic mechanism underlying APD shortening by 
progesterone is to modulate IKs and ICa,L, but not IKr. In the 
basal condition, progesterone enhanced IKs in a concentra-
tion-dependent manner with an EC50 value of 2.7 nM, while 
progesterone did not significantly affect ICa,L (Fig. 2A) [30]. 
SNS-stimulation caused enhancement of both ICa,L and IKs.
Further application of progesterone reduced ICa,L to the level 
before cAMP and OA application, while it did not signifi-
cantly change IKs [30]. The IC50 value for ICa,L suppression 
was 29.9 nM (Fig. 2B). 
  The biophysical mechanism for regulation of IKs and ICa,L
is different. The effects of progesterone on IKs were fre-
quency- and voltage-independent [30]. In contrast, proges-
terone caused a positive shift in the ICa,L activation curve and 
a negative shift in the inactivation curve [30]. Computer 
simulation analysis showed that changes in current conduc-
Fig. (1). Genomic and non-genomic pathway of sex hormones. 
In the genomic pathway, sex steroid hormones penetrate into cells, and bind to receptors in the cytosol. The ligand/receptor complex then 
translocates into the nucleus, binds to the genes with hormone responsive element (HRE), and regulates gene expression. In the non-genomic 
pathway, sex hormones release nitric oxide via the PI3-kinase/Akt/eNOS pathway or activate MAP-kinase in a membrane-delimited manner. 246 Current Cardiology Reviews, 2008, Vol. 4, No. 4 Furukawa et al. 
tance without changes in current kinetics reproduced the ef-
fects of progesterone on IKs observed in biological experi-
ments. Changes in voltage dependency alone with no change 
in current conductance reproduced the effects of progester-
one on ICa,L with a high accuracy. Thus, effects of progester-
one on IKs are mainly to alter current conductance and modu-
late ICa,L by affecting current kinetics. 
  Despite distinct biophysical mechanism for IKs and ICa,L
regulation, the principal mediator for both IKs enhancement 
in the basal condition and ICa,L suppression in the SNS-
stimulated condition appears to be nitric oxide (NO), since 
both were abolished by nitric oxide (NO) trappers and eNOS 
inhibitors [31, 32]. However, the mechanism by which NO 
modulates IKs and ICa,L appears to be different. ICa,L suppres-
sion by progesterone was abolished by an inhibitor of soluble 
guanylyl cyclase (sGC), indicating that ICa,L is regulated by 
progesterone via a NO/sGC/cGMP axis (Fig. 3) [33]. An-
tagonistic action of cAMP and cGMP for ICa,L has been dem-
onstrated, which appears to vary among species [34]. In rab-
bit and frog ventricular myocytes, cGMP antagonizes cAMP 
effects by promoting cAMP breakdown by activating cGMP-
dependent phosphodiesterase (PDE2) [34]. In guinea-pig and 
rat ventricular myocytes, cAMP-dependent protein kinase 
(PKA) phosphorylates the -subunit of ICa,L and enhances 
ICa,L only in the presence of A-kinase anchoring protein 
(AKAP) [34]. cGMP-dependent protein kinase (PKG) phos-
phorylates both the -subunit and the -subunit of ICa,L [35]. 
Phosphorylation of the -subunit by PKG does not affect 
ICa,L, likely due to the absence of AKAP, while phosphoryla-
tion of the -subunit antagonizes the effect of the -subunit 
phosphorylation by PKA [35]. In addition, the inhibition of 
PDE3 by cGMP to enhance the cAMP-induced activation 
and facilitation of ICa,L, and activation of protein phosphatase 
via cGMP-PKG signaling pathway to suppress the cAMP-
mediated facilitation may contribute to the complicated in-
teraction of cAMP and cGMP in the heart. 
  On the other hand, IKs enhancement was not inhibited by 
a sGC inhibitor, but was inhibited by a thiol-alkylating rea-
gent,  N-ethylmaleimide, and a reducing reagent, di-thio-
threitol [33]. These data suggest that cGMP-independent 
mechanisms, possibly protein s-nitrosylation, play a role for 
IKs enhancement (Fig. 3) [33]. Protein s-nitrosylation is the 
direct NO transfer to the thiol residue of Cys, is highlighted 
as a novel mechanism of protein post-translational modifica-
tion [36, 37], and occurs independent of cAMP. Thus, it is 
possible that progesterone regulates IKs in the basal condition 
and ICa,L only in the SNS-stimulated condition. However, it 
remains to be proven if the IKs channel is indeed s-nitro-
sylated. If that is the case, it is also undetermined whether 
the -subunit, KCNQ1, or the -subunit, KCNE1, is the tar-
get of s-nitrosylation, what is the underlying mechanism for 
specific s-nitrosylation of KCNQ1 or KCNE1, and how s-
nitrosylation induces IKs channel activation.  
4. COMPUTATIONAL SIMULATION OF THE EF-
FECTS OF PROGESTERONE 
 QTc interval and TdP risk are regulated by various fac-
tors, including SNS status, heart rate, medications, serum 
electrolyte level, and others. Our biological experiments 
suggest progesterone as an additional major factor that 
modulates QTc interval and TdP risk. Since progesterone 
Fig. (2). Two distinct mechanisms for NO actions. 
NO activates sGC, and produced cGMP regulates PKG, PDE2, PDE3, and/or protein phosphatase (PPase). NO also induces protein s-
nitrosylation. ICa,L suppression by progesterone is via the sGC/cGMP pathway, while IKs activation is via the protein s-nitrosylation. Inset 
shows the antagonistic action between cAMP and cGMP for ICa,L regulation. It has been reported that in rabbit and frog ventricular myocytes, 
it occurs at the PDE2 level, while in guinea-pig and rat ventricular myocytes, it occurs at the PKG level [34]. The inhibition of PDE3 by 
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level varies during the menstrual cycle and around delivery, 
progesterone effects may contribute to the fluctuation of QTc
interval and TdP risk during the menstrual cycle and preg-
nancy. Since a computational approach is especially power-
ful to simulate these changes, our first challenge was to in-
vestigate if incorporating effects of progesterone in the car-
diac APD computer model reproduces fluctuation of APD 
during the menstrual cycle.  
  We incorporated effects of progesterone obtained in our 
biological experiments in the Faber-Rudy model of the 
guinea pig myocyte [38]. Since reported progesterone level 
in women is ~2.5 nM in the follicular phase and ~40.6 nM in 
the luteal phase [39], we incorporated effects of progesterone 
at 2.5 nM and at 40.6 nM. The model predicts that proges-
terone at 40.6 nM shortens APD by 3.7 % under basal condi-
tions and 4.6 % under SNS-stimulated conditions compared 
to APD at 2.5 nM progesterone (Fig. 4) [30]. Clinically ob-
served QT intervals are shorter by about 2.4%-2.8 % in the 
luteal phase than in follicular phase [5], and so the APD 
shortening predicted in the model (3.7-4.6 %) fits well with 
the observed fluctuation in QT interval during the menstrual 
cycle in women.  
  Effects of progesterone in a single cell do not necessarily 
predict the effect at the multi-cell level, organ level, or in
vivo level. As a first step to simulate effects of progesterone 
in higher dimensions, we constructed a coupled-cells model, 
in which 100 cardiomyocytes are electrotonically connected 
with simulated resistances between them to represent gap-
junctions. We then investigated the effects of progesterone 
and SNS in simulated coupled tissue and computed virtual 
electrograms from simulated gradients of depolarization and 
repolarization. Simulations suggest that during the luteal 
phase when progesterone = 40.6 nM, maximal SNS may 
additionally shorten QT interval by 12.2 % (Fig. 4) [30]. 
These simulations support the notion that progesterone may 
exert protective QT shortening effects under conditions on 
SNS. 
5. PREDICTED EFFECTS OF PROGESTERONE 
AGAINST ARRHYTHMIA 
  Since the model reproduces the effects of progesterone 
on APD in patch-clamp experiments and QTc variation dur-
ing the menstrual cycle in women with a good accuracy, our 
next step was to utilize this model to predict the effects of 
progesterone on LQTS-associated arrhythmia susceptibility. 
To examine the effects on SNS-induced arrhythmias, we 
used the D76N KCNE1 mutation linked to congenital 
LQTS5. IKs exhibits accumulation in the pre-open state dur-
ing the rapid heart rates, resulting in action potential adapta-
tion [40]. SNS stimulation enhances ICa,L to increase Ca
2+
influx [41]. SNS stimulation also enhances IKs [42, 43] that 
counter-balances ICa,L enhancement and maintains APD 
within a certain range [44]. In LQTS1 and LQTS5, IKs chan-
nel disturbance results in dysfunction of action potential ad-
aptation to rapid heart rates and response to SNS stimulation. 
Fig. (3). Non-genomic regulation of IKs and ICa,L by progesterone in patch-clamp experiments. 
A) In the basal condition, progesterone (P4) enhances IKs. a, Representative superimposed IKs current traces in the control and after treatment 
with 100 nM P4. IKs was elicited by depolarization to +50 mV from a holding potential of -40 mV at 0.1 Hz. b, Concentration-response curve 
for IKs enhancement by progesterone. EC50 was 2.6 nM. 
B) In the SNS-stimulation-mimicked condition, progesterone suppressed ICa,L. a, Representative superimposed ICa,L current traces in the con-
trol, during intracellular dialysis of cAMP and OA, and after treatment with 100 nM P4 in the continued presence of cAMP and OA. ICa,L
was elicited by depolarization from a holding potential of -40 mV to 0 mV at 0.1 Hz. b, Concentration-response curve for ICa,L suppression 
by progesterone. IC50 was 29.9 nM. 248 Current Cardiology Reviews, 2008, Vol. 4, No. 4 Furukawa et al. 
The D76N KCNE1 mutation reduces the current and renders 
the IKs channel insensitive to adrenergic stimulation [45], 
thus probands carrying D76N KCNE1 mutation readily de-
velop TdP with SNS stimulation at rapid heart rates [46]. In 
the absence of progesterone, the mutant model cells are un-
able to adapt to the fast pacing frequency because IKs fails to 
increase in response tothe SNS stimulation (Fig. 5A) [30]. 
Interestingly, both in the single-cell and coupled-cell model 
in the presence of progesterone at 2.5 nM, some improve-
ment is observed; in the presence of 40.6 nM, a failed SNS 
stimulation response is compensated for by the action of 
progesterone alone to increase IKs (Fig. 5A) [30]. Thus, en-
hancement of IKs in the absence of SNS stimulation, and in-
hibition of cAMP-induced ICa,L by progesterone improve 
action potential adaptation, which is dependent on progester-
one level. These simulations suggest a mechanism for SNS-
related arrhythmic risk varies during the menstrual cycle in 
women.  
  Drug-induced TdP is believed to occur by blockade of 
the  human ether-a-go-go related gene ( hERG) channel by 
drugs with various structures [47], and at slow heart rates. In 
a simulation, severe EADs were induced by 50% block of IKr
at a slow heart rate (30 bpm) (Fig. 5B). At 2.5 nM of proges-
terone, some improvement is observed (middle panel); at 
40.6 nM of progesterone, the EADs are abolished and the 
action potential morphology is normalized (Fig. 5B). Thus, 
progesterone is predicted to have protective effects against 
drug-induced arrhythmias, which also fluctuate during the 
menstrual cycle. Progesterone does not have apparent effects 
on IKr (data not shown), and thus predicted protection against 
drug-induced EAD may be attributed to an increase in repo-
larization reserve by IKs enhancement [48].  
CONCLUSION 
  Our patch-clamp experiment demonstrates that the non-
genomic effect of the sex hormone progesterone constitutes a 
novel regulatory mechanism of cardiac repolarization. Serum 
progesterone level fluctuates during the menstrual cycle: 
within this level, progesterone modulates IKs and ICa,L and, 
therefore, is partly responsible for the cyclic changes in QTc
interval and TdP risk during the menstrual cycle. A computa-
tional approach allows for simulation of multi-factorial and 
periodical phenomenon. Incorporation of progesterone ef-
fects observed in our biological study into the computational 
model reproduces cyclic changes in QTc interval, and pre-
dicts dose-dependent protective effects of progesterone 
against SNS-stimulation-induced and drug-induced arrhyth-
mias. This approach provides a first step to risk stratify TdP 
Fig. (4). The effects of progesterone on simulated cardiac action potentials. 
A) Simulated action potentials in the absence (a) and presence (b) of simulated SNS stimulation under baseline conditions (dashed line) and 
with 2.5 nM (solid line) and 40.6 nM (dashed-dot-dot line) progesterone. The 10th paced beat at a pacing interval of 400 ms is shown.  
B) Left panel: Simulated action potentials (10th paced beat at a 400 ms pacing interval) in a 1 cm cardiac fiber (cell number=100; top is cell 
#1, and bottom is cell #100). An action potential was elicited at cell #1, and propagated from top to bottom. a, Baseline (no SNS stimulation 
and no progesterone). b, With 40.6 nM progesterone. c, With 40.6 nM progesterone in the presence of SNS stimulation. Right panel: Com-
puted virtual electrograms under the three conditions. The corresponding T-waves are indicated with arrows. A Combined Approach Using Patch-Clamp Study  Current Cardiology Reviews, 2008, Vol. 4, No. 4    249
arrhythmias in women. To improve this approach, further 
efforts are certainly needed, which include the elucidation of; 
(1) the effects of sex hormones other than progesterone, in-
cluding various estrogen metabolites; (2) genomic effects of 
progesterone and estrogens; and (3) simulation at the organ 
and in vivo level. 
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